Latest period
−$27.09M
YoY change
+9.2%
5Y CAGR
—
Peak year (2021)
−$9.26M
Latest annual
−$51.77M
Operating Cash Flow history chart for Alto Neuroscience (ANRO) from 2021 to 2025
Latest: −$51.77M
Operating Cash Flow growth chart for Alto Neuroscience (ANRO) from 2021 to 2025
Latest: +9.2%
Operating Cash Flow history table for Alto Neuroscience (ANRO) from 2021 to 2025
| 2025 | −$51.77M | +9.2% | −$4.34M | ||
| 2024 | −$47.42M | +41.8% | −$13.98M | ||
| 2023 | −$33.45M | +64.0% | −$13.05M | ||
| 2022 | −$20.39M | +120.2% | −$11.13M | ||
| 2021 | −$9.26M | — | — |
- 2025−$51.77M+9.2%
- 2024−$47.42M+41.8%
- 2023−$33.45M+64.0%
- 2022−$20.39M+120.2%
- 2021−$9.26M—
Operating Cash Flow values are taken from Alto Neuroscience's reported cash flow statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Operating Cash Flow at Alto Neuroscience (ANRO)
Operating Cash Flow for Alto Neuroscience (ANRO): headline value −$27.09M · YoY +9.2%. Annual and quarterly series, chart, and tables are below.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
In 2025, Alto Neuroscience (ANRO) operating cash flow totalled −$51.77M – grew 9.2% year-over-year.
The highest annual operating cash flow of −$9.26M was reported in 2021. The lowest in the available history was −$51.77M in 2025.
Alto Neuroscience Operating Cash Flow by Year
Alto Neuroscience Operating Cash Flow 2025: −$51.77M
Alto Neuroscience posted operating cash flow of −$51.77M in 2025, grew 9.2% from 2024. This figure represents the lowest annual value in the available history.
Alto Neuroscience Operating Cash Flow 2024: −$47.42M
In 2024, Alto Neuroscience reported operating cash flow of −$47.42M, surged 41.8% from 2023.
Alto Neuroscience Operating Cash Flow 2023: −$33.45M
Alto Neuroscience operating cash flow in 2023 was −$33.45M, surged 64.0% from 2022.
Alto Neuroscience Operating Cash Flow 2022: −$20.39M
2022's operating cash flow for Alto Neuroscience came in at −$20.39M, surged 120.2% from 2021.
Alto Neuroscience Operating Cash Flow 2021: −$9.26M
Alto Neuroscience operating cash flow in 2021 was −$9.26M.
See more financial history for Alto Neuroscience (ANRO).
Sector peers by Operating Cash Flow
Healthcare peers of Alto Neuroscience (ANRO), ranked by their latest operating cash flow
| $24.53B | |
| $19.70B | |
| $19.03B | |
| $18.56B | |
| $16.81B | |
| $16.47B | |
| $14.57B | |
| $9.96B |
- $24.53B
- $19.70B
- $19.03B
- $18.56B
- $16.81B
- $16.47B
- $14.57B
- $9.96B
Frequently asked questions
Alto Neuroscience (ANRO) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation